I. Grenga

发表

Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody

J. Schlom, R. Madan, J. Gulley, 2017, Journal of Immunotherapy for Cancer.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Manish R. Patel, Charles J. Vaske, Joe Y. Chang, 2016, Journal for Immunotherapy of Cancer.

The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells

M. Brechbiel, J. Schlom, R. Madan, 2016, Oncotarget.

An activated protein C-dependent thrombin generation assay predicts chemotherapy-associated venous thromboembolism in cancer patients

F. Guadagni, S. Riondino, P. Ferroni, 2011, Thrombosis and Haemostasis.

Role of CA19.9 in predicting bevacizumab efficacy for metastatic colorectal cancer patients.

V. Formica, M. Roselli, F. Skoulidis, 2009, Cancer biomarkers : section A of Disease markers.

Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury

J. Schlom, R. Madan, W. Dahut, 2015, Cancer Immunology Research.

Identification by digital immunohistochemistry of intratumoral changes of immune infiltrates after vaccine in the absence of modifications of PBMC immune cell subsets

M. Merino, P. Pinto, J. Schlom, 2014, International journal of cancer.

Early changes of a novel APC-dependent thrombin generation assay during chemotherapy independently predict venous thromboembolism in cancer patients—a pilot study

F. Guadagni, F. Farina, S. Riondino, 2012, Supportive Care in Cancer.

Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors

J. Schlom, R. Madan, J. Marté, 2018, Clinical Cancer Research.

Phase 1 trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in advanced solid tumors

Zhigang, Kang, J. Schlom, 2017 .

Immune Consequences of Decreasing Tumor Vasculature with Antiangiogenic Tyrosine Kinase Inhibitors in Combination with Therapeutic Vaccines

A. Molinolo, R. Donahue, J. Hodge, 2014, Cancer Immunology Research.

Inhibition of the angiopoietin/Tie2 axis induces immunogenic modulation, which sensitizes human tumor cells to immune attack

R. Donahue, J. Hodge, I. Grenga, 2015, Journal of Immunotherapy for Cancer.

The association of clinical outcome and peripheral T-cell subsets in metastatic colorectal cancer patients receiving first-line FOLFIRI plus bevacizumab therapy

F. Guadagni, J. Schlom, A. Orlandi, 2016, Oncoimmunology.

A fully human IgG1 anti-PD-L1 MAb in an in vitro assay enhances antigen-specific T-cell responses

J. Schlom, R. Donahue, Jacob Richards, 2016, Clinical & translational immunology.

Pan-Bcl-2 Inhibitor, GX15-070 (Obatoclax), Decreases Human T Regulatory Lymphocytes while Preserving Effector T Lymphocytes: A Rationale for Its Use in Combination Immunotherapy

J. Schlom, P. Kim, J. Gulley, 2014, The Journal of Immunology.

Combination Immunotherapy Lymphocytes: A Rationale for Its Use in Lymphocytes while Preserving Effector T Decreases Human T Regulatory Pan-Bcl-2 Inhibitor, GX15-070 (Obatoclax),

J. Schlom, J. Gulley, C. Jochems, 2014 .

Abstract 4901: Short-course enzalutamide reveals immune activating properties in patients with biochemically recurrent prostate cancer

J. Schlom, R. Madan, J. Gulley, 2016 .

OA18.03 Safety and Clinical Activity of Avelumab (MSB0010718C; Anti-PD-L1) in Patients with Advanced Thymic Epithelial Tumors (TETs)

A. Mammen, S. Pittaluga, J. Schlom, 2017 .

Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab

F. Guadagni, V. Formica, R. Palmirotta, 2011, International Journal of Colorectal Disease.

Samarium-153-EDTMP (Quadramet®) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial

Walter M. Stadler, Christopher R. Heery, James L. Gulley, 2016, Oncotarget.

Docetaxel Alone or in CombinationWith a Therapeutic Cancer Vaccine ( PANVAC ) in PatientsWithMetastatic Breast Cancer A Randomized Clinical Trial

S. Steinberg, N. Ibrahim, J. Murray, 2015 .

Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients Not Detected in Analysis of Standard Immune Cell Types

Christopher R. Heery, James L. Gulley, Jacob Richards, 2016, Journal of circulating biomarkers.

Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis.

J. Schlom, M. Roselli, Marijo Bilusic, 2017, Urologic oncology.

Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.

J. Schlom, A. Heydebreck, R. Madan, 2017, The Lancet. Oncology.

Abstract CT011: NeoCOAST: open-label, randomized, phase 2, multidrug platform study of neoadjuvant durvalumab alone or combined with novel agents in patients (pts) with resectable, early-stage non-small-cell lung cancer (NSCLC)

J. Blando, J. Mazières, Y. Zheng, 2022, Cancer Research.

Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury

J. Schlom, R. Madan, W. Dahut, 2017, Clinical Cancer Research.

Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy

N. Ibrahim, J. Schlom, R. Madan, 2016, Cancer Immunology Research.

Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial.

S. Steinberg, N. Ibrahim, J. Murray, 2015, JAMA oncology.

Caregiver distress in the early phases of cancer.

V. Formica, M. Roselli, I. Grenga, 2010, Anticancer research.

PD-1 and PD-L1 expression on PBMC subsets in normal individuals and cancer patients

J. Schlom, R. Madan, J. Gulley, 2014, Journal of Immunotherapy for Cancer.

Pharmacokinetic profile and receptor occupancy of avelumab (MSB0010718C), an anti-PD-L1 monoclonal antibody, in a phase I, open-label, dose escalation trial in patients with advanced solid tumors.

J. Schlom, R. Madan, J. Marté, 2015 .

Rehabilitation in Neuro-Oncology: A Meta-Analysis of Published Data and a Mono-Institutional Experience

Salvatore Giaquinto, V. Formica, M. Roselli, 2011, Integrative cancer therapies.

Changes in multiparametric prostate MRI and immune subsets in patients (Pts) receiving neoadjuvant immunotherapy and androgen deprivation therapy (ADT) prior to radiation.

P. Choyke, P. Pinto, B. Turkbey, 2017 .

929MO Platform study of neoadjuvant durvalumab (D) alone or combined with novel agents in patients (pts) with resectable, early-stage non-small cell lung cancer (NSCLC): Pharmacodynamic correlates and circulating tumor DNA (ctDNA) dynamics in the NeoCOAST study

J. Blando, O. Hamid, P. Forde, 2022, Annals of Oncology.

Effect of age and cancer on peripheral immune cell subsets and their PD-1 and PD-L1 expression

J. Schlom, R. Madan, J. Gulley, 2015, Journal of Immunotherapy for Cancer.

Evaluation of immune cell subsets of cancer patients treated with Avelumab, a fully human IgG1 anti-PD-L1 MAb capable of mediating ADCC of human tumor cells

J. Schlom, R. Madan, J. Gulley, 2015, Journal of Immunotherapy for Cancer.

Phase I, dose-escalation, clinical trial of MVA-Brachyury-TRICOM vaccine demonstrating safety and brachyury-specific T cell responses

J. Schlom, R. Madan, J. Gulley, 2015, Journal of Immunotherapy for Cancer.

Peripheral CD45RO, PD-1, and TLR4 expression in metastatic colorectal cancer patients treated with bevacizumab, fluorouracil, and irinotecan (FOLFIRI-B)

F. Guadagni, P. Ferroni, V. Formica, 2013, Medical Oncology.

PD-L1 and MHC-I expression in 19 human tumor cell lines and modulation by interferon-gamma treatment

J. Schlom, R. Donahue, Lauren M. Lepone, 2014, Journal of Immunotherapy for Cancer.

Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.

J. Schlom, A. Heydebreck, R. Madan, 2017, The Lancet. Oncology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.

Effects of tyrosine kinase inhibitors alone or in combination with vaccine on tumor-infiltrating myeloid cells

J. Schlom, R. Donahue, I. Grenga, 2013, Journal of Immunotherapy for Cancer.